Market Overview

UPDATE: Citigroup Lowers PT on Quest Diagnostics Following Disappointing 3Q13 Results

Share:
Related DGX
Earnings Scheduled For October 19, 2017
Benzinga's Top Upgrades, Downgrades For October 12, 2017
Quest Diagnostics takes issue with new 2018 Medicare reimbursement schedule, 4% cut expected (Seeking Alpha)

In a report published Friday, Citigroup analyst Gary Taylor reiterated a Neutral rating on Quest Diagnostics (NYSE: DGX), but lowered the price target from $64.00 to $60.00.

In the report, Citigroup noted, “DGX previewed disappointing 3Q13 results this morning after mounting a spirited defense of its guidance on its 7/18/13 2Q13 conference call. More recently, on 9/18/13 we hosted a management roadshow in Chicago. The key takeaway from our note was as follows ‘Mgmt is sticking to its 2014 double-digit EPS growth target while maintaining that they've seen no material recent change in industry trends.' Obviously, it's difficult to square these outlooks with the reported results.”

Quest Diagnostics closed on Thursday at $58.66.

Latest Ratings for DGX

DateFirmActionFromTo
Oct 2017Canaccord GenuityMaintainsBuy
Oct 2017Wells FargoMaintainsMarket Perform
Oct 2017CitigroupMaintainsNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Citigroup Gary TaylorAnalyst Color Price Target Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!

Partner Center